CYP19A1 and breast carcinoma: According to the POETIC clinical phase-3 trial, Ki67 variation in women with operable ER-positive primary breast cancer after preoperative and perioperative aromatase inhibitor (POAI) therapy assisted in deciding further adjuvant endocrine therapy and chemotherapy [19].